Clinical Trials Browser

NCT04842877 2026-02-19

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Phase 2 Active not recruiting

141 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT06723457 2026-02-17

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

Phase 2 Active not recruiting

34 enrolled

Lymphoid

Lymphoma, B-Cell

NCT05583149 2026-01-29

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Phase 2 Active not recruiting

28 enrolled 6 charts

Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT04594798 2025-12-17

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Phase 2 Active not recruiting

39 enrolled

Lymphoid

Lymphoma, B-Cell

NCT05410418 2025-12-15

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Phase 2 Active not recruiting

34 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell

NCT03038672 2025-11-10

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Phase 2 Active not recruiting

54 enrolled 12 charts

Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT04148430 2025-11-05

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Phase 2 Active not recruiting

62 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

NCT04245839 2025-11-05

TRANSCEND FL

Phase 2 Active not recruiting

276 enrolled 2 FDA

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03888105 2025-10-15

ELM-2

Phase 2 Active not recruiting

515 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05507541 2025-08-29

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

10 enrolled

Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03505762 2025-08-20

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

Phase 2 Active not recruiting

80 enrolled

Lymphoid

Lymphoma, B-Cell

NCT05020015 2025-08-12

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 2 Active not recruiting

27 enrolled 23 charts

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT07094477 2025-07-30

Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma

Phase 2 Active not recruiting

50 enrolled

Lymphoid

Lymphoma, Lymphoma, B-Cell

NCT03995147 2025-06-08

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Phase 2 Active not recruiting

51 enrolled

Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05263583 2025-01-14

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Phase 2 Active not recruiting

14 enrolled

Lymphoid

Burkitt Lymphoma, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04234061 2024-11-07

TARMAC

Phase 2 Active not recruiting

20 enrolled

Lymphoid

Lymphoma, B-Cell

NCT03620578 2024-02-14

HO152

Phase 2 Active not recruiting

97 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell